Preparation of 177Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A″-DTPA as bifunctional chelators
dc.contributor.author | Pandey, U. | |
dc.contributor.author | Kameswaran, M. | |
dc.contributor.author | Gamre, N. | |
dc.contributor.author | Dash, A. | |
dc.date.accessioned | 2020-11-09T06:26:53Z | |
dc.date.available | 2020-11-09T06:26:53Z | |
dc.date.issued | 2019 | |
dc.description.division | RPhD | en |
dc.format.extent | 4883 bytes | |
dc.format.mimetype | text/html | |
dc.identifier.source | Journal of Labelled Compounds and Radiopharmaceuticals, 2019. Vol. 62: pp. 158-165 | en |
dc.identifier.uri | http://hdl.handle.net/123456789/21220 | |
dc.language.iso | en | en |
dc.subject | EGFR | en |
dc.subject | Nimotuzumab | en |
dc.subject | radioimmunotherapy | en |
dc.subject | 177Lu‐CHX‐A″‐DTPA‐Nimotuzumab | en |
dc.subject | 177 Lu‐DOTA‐Nimotuzumab | en |
dc.title | Preparation of 177Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A″-DTPA as bifunctional chelators | en |
dc.type | Article | en |